Synapse Surgery Fusion Proteins for Circuit-Specific Synapse Ablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tools for manipulating neural connections are limited by optical approaches that are low-throughput, invasive, and non-specific, hindering effective brain-wide neural circuit manipulation, which is crucial for understanding and addressing neurological disorders.
Innovation Solution
Fusion proteins comprising an activated glial receptor binding domain and a transmembrane domain of synaptic proteins, such as C3dg or Gas6, are used to target and remove specific synapses by engaging activated microglial cells, enabling precise synapse ablation and modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If optical approaches (optogenetic tools) are used to control neural activities, then circuit-specific control is achieved, but the method suffers from low throughput, technical complexity, and procedural invasiveness
Solution Approach 1:
The patent replaces optical control mechanisms with a biochemical mechanism. Fusion proteins comprising a transmembrane domain and a glial cell binding domain are expressed in neurons, enabling glial cells to directly bind to and eliminate specific synapses through biochemical interactions rather than optical stimulation. This substitution eliminates the need for complex optical equipment and procedures while dramatically increasing throughput.
Solution Approach 2:
The patent introduces fusion proteins as intermediary molecules that mediate between neurons and glial cells. These fusion proteins contain a transmembrane domain anchored in the neuron and a glial cell binding domain extending outward, serving as a molecular bridge that enables specific glial cell recognition and binding to target synapses without requiring optical intervention.
2Duration of action of moving object
If optical approaches are used for neural manipulation, then temporal control of neural activities is achieved, but the method is procedurally invasive
Solution Approach 1:
The patent replaces invasive optical procedures with a non-invasive biochemical approach. By expressing fusion proteins in target neurons, the system enables glial cells to naturally seek out and bind to specific synapses through molecular recognition, eliminating the need for cranial windows, fiber optic implants, or other invasive optical hardware.
3Measurement precision
If current tools are used for neural circuit manipulation, then specific neural activities can be controlled, but brain-wide neural circuit manipulation is hindered
Solution Approach 1:
The patent creates a universal platform for neural circuit manipulation by using fusion proteins that can be applied across different brain regions and neural circuits. The same basic mechanism—expressing fusion proteins in target neurons and recruiting glial cells—can be used throughout the brain, providing both specificity for individual circuits and versatility for brain-wide applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for highly specific and efficient manipulation of neural circuits, facilitating the study and treatment of neurological disorders by selectively removing aberrant synapses, thus improving our understanding and treatment of conditions like depression, anxiety, and neurodegenerative diseases.
Implementation Method 1
an N terminal domain comprising an activated glial receptor binding domain
Data Source
AI summary
A synapse surgical tool for selectively removing or ablating a postsynaptic terminal from a neuron, the method comprising: delivering an expression vector comprising a nucleic acid encoding a fusion protein comprising an N-terminal domain comprising an activated glial receptor binding domain; and a C terminal domain comprising a transmembrane domain of postsynaptic protein; expressing the fusion protein so that the activated glial receptor binding domain is localized to a synaptic cleft of the postsynaptic terminal of the neuron; and contacting the neuron with an activated microglial cell so that the activated microglial binds to the activated glial receptor binding domain and selectively ablates the postsynaptic terminal of the neuron.